# Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer

> **NCT04030260** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 28 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic
- MSS

## Interventions

- **DRUG:** Regorafenib and PD-1 antibody in Combination with Radiotherapy
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT04030260
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-19
- **Primary completion:** 2023-02-20
- **Final completion:** 2023-07-19
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2023-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04030260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04030260, "Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04030260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*